BCL2L12 and central nervous system cancer: To distinguish whether BCL2L12 is regulated by the proteasome or lysosome mediated degradation pathways, we conducted rescue experiments in EYA1 knockdown glioma cells using the proteasome inhibitor MG132 and the lysosome inhibitor chloroquine (CQ).